Amexdrug Corp. (AXRX) Financials Nov 10, 2014, 8:10 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Amexdrug Corp.
Fiscal year is January-December. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 9.77M 11.49M 11.49M 9.15M 8.51M
Cost of Goods Sold (COGS) incl. D&A 9.05M 10.53M 10.53M 8.16M 7.58M
COGS excluding D&A 9.05M 10.52M 10.52M 8.14M 7.52M
Depreciation & Amortization Expense 8,241 8,102 8,102 19,538 58,847
Depreciation 8,076 7,938 7,938 19,373 58,682
Amortization of Intangibles 165 164 164 165 165
Gross Income 713,568 954,576 954,576 987,022 931,440
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 657,872 664,148 664,148 791,167 1.01M
Research & Development 123,328 0 0 0 0
Other SG&A 534,544 664,148 664,148 791,167 1.01M
Other Operating Expense 0 0 0 0 0
Unusual Expense 5,222 (2,584) (2,584) (1,864) (1,711)
EBIT after Unusual Expense (5,222) 2,584 2,584 1,864 1,711
Non Operating Income/Expense 0 (3,341) (3,341) 0 135,401
Non-Operating Interest Income 0 1,668 1,668 3 205
Equity in Affiliates (Pretax) 0 0 0 0 0
Interest Expense 23,268 25,486 25,486 38,033 47,139
Gross Interest Expense 23,268 25,486 25,486 38,033 47,139
Interest Capitalized - - - 0 0
Pretax Income 27,206 265,853 265,853 159,689 13,441
Income Tax 8,860 76,791 76,791 77,655 (10,995)
Income Tax - Current Domestic - - - 800 81,000
Income Tax - Current Foreign - - - - -
Income Tax - Deferred Domestic - - - 76,855 (91,995)
Income Tax - Deferred Foreign - - - - -
Income Tax Credits 8,860 - - 0 0
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income 18,346 189,062 189,062 82,034 24,436
Minority Interest Expense 0 0 0 0 0
Net Income 18,346 189,062 189,062 82,034 24,436
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg - - - 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries 18,346 189,062 189,062 82,034 24,436
Preferred Dividends 0 0 0 0 0
Net Income Available to Common 18,346 189,062 189,062 82,034 24,436
EPS (Basic) 0.00 0.00 0.00 0.00 0.00
Basic Shares Outstanding 169.41M 169.41M 169.41M 169.41M 169.41M
EPS (Diluted) 0.00 0.00 0.00 0.00 0.00
Diluted Shares Outstanding 169.41M 169.41M 169.41M 169.41M 169.41M
EBITDA 63,937 298,530 298,530 215,393 (17,890)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Amexdrug Corp.
Fiscal year is January-December. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 9.77M 11.49M 11.49M 9.15M 8.51M
Cost of Goods Sold (COGS) incl. D&A 9.05M 10.53M 10.53M 8.16M 7.58M
COGS excluding D&A 9.05M 10.52M 10.52M 8.14M 7.52M
Depreciation & Amortization Expense 8,241 8,102 8,102 19,538 58,847
Depreciation 8,076 7,938 7,938 19,373 58,682
Amortization of Intangibles 165 164 164 165 165
Gross Income 713,568 954,576 954,576 987,022 931,440
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 657,872 664,148 664,148 791,167 1.01M
Research & Development 123,328 0 0 0 0
Other SG&A 534,544 664,148 664,148 791,167 1.01M
Other Operating Expense 0 0 0 0 0
Unusual Expense 5,222 (2,584) (2,584) (1,864) (1,711)
EBIT after Unusual Expense (5,222) 2,584 2,584 1,864 1,711
Non Operating Income/Expense 0 (3,341) (3,341) 0 135,401
Non-Operating Interest Income 0 1,668 1,668 3 205
Equity in Affiliates (Pretax) 0 0 0 0 0
Interest Expense 23,268 25,486 25,486 38,033 47,139
Gross Interest Expense 23,268 25,486 25,486 38,033 47,139
Interest Capitalized - - - 0 0
Pretax Income 27,206 265,853 265,853 159,689 13,441
Income Tax 8,860 76,791 76,791 77,655 (10,995)
Income Tax - Current Domestic - - - 800 81,000
Income Tax - Current Foreign - - - - -
Income Tax - Deferred Domestic - - - 76,855 (91,995)
Income Tax - Deferred Foreign - - - - -
Income Tax Credits 8,860 - - 0 0
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income 18,346 189,062 189,062 82,034 24,436
Minority Interest Expense 0 0 0 0 0
Net Income 18,346 189,062 189,062 82,034 24,436
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg - - - 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries 18,346 189,062 189,062 82,034 24,436
Preferred Dividends 0 0 0 0 0
Net Income Available to Common 18,346 189,062 189,062 82,034 24,436
EPS (Basic) 0.00 0.00 0.00 0.00 0.00
Basic Shares Outstanding 169.41M 169.41M 169.41M 169.41M 169.41M
EPS (Diluted) 0.00 0.00 0.00 0.00 0.00
Diluted Shares Outstanding 169.41M 169.41M 169.41M 169.41M 169.41M
EBITDA 63,937 298,530 298,530 215,393 (17,890)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
